CITRULLINATION OF HUMAN PEPTIDYLARGININE DEIMINASE 4 (PAD-4) REGULATES ITS FUNCTION AND IMMUNOGENICITY
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Apr 25, 2013
app pub date -
Nov 24, 2010
filing date -
Nov 25, 2009
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention provides peptidylarginine deiminase 4 (PAD-4) polypeptides comprising one or more citrullinated Arginine sites. In one embodiment, a PAD-4 polypeptide comprises a citrulline residue at the following sites: Arg-205, Arg-212, Arg-218, Arg-372, Arg-374, Arg-383, Arg-394, Arg-495, Arg-536, and Arg-544. The present invention also provides methods for detecting the presence of autoantibodies to citrullinated PAD-4. The methods of the present invention may also be used to qualify Rheumatoid Arthritis status in a subject. In other embodiments, the present invention provides methods for inducing tolerance to citrullinated PAD-4.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully